Literature DB >> 7588996

Metabolism of levomepromazine in man.

P A Hals1, S G Dahl.   

Abstract

The phenothiazine drug, levomepromazine (LM), is used in the treatment of psychiatric disorders and as an analgesic. A single 50 or 100 mg dose of LM was given to healthy male volunteers, and urine samples were collected for 24 h. The urine was treated with beta-glucuronidase, purified by solid-phase extraction, and analyzed on a GC-MS system for identification of LM metabolites. Mass spectra suggesting 14 different LM metabolites were obtained from the samples. Our of these, 13 spectra could be ascribed to specific metabolites, 5 of which have not previously been identified. All these 5 metabolites were hydroxylated at the phenothiazine nucleus. Although the applied method did not determine the positions of hydroxyl groups on phenothiazine nuclei. 3 of the 5 metabolites were identified as O-desmethyl 3-hydroxy LM, O-desmethyl 7-hydroxy LM, and N,O-didesmethyl 7-hydroxy LM, based on their chromatographic properties. In addition two metabolites, one being hydroxylated on the phenothiazine nucleus, and one being O-demethylated and hydroxylated on the nucleus, were found. It is suggested that these were 8-hydroxy LM and O-desmethyl 8-hydroxy LM. The concentrations of 3-hydroxy LM (free+conjugated) appeared to be much higher than the concentrations of any other metabolite in the samples.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7588996     DOI: 10.1007/BF03192290

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  19 in total

1.  Chromatographic evidence for the existence of 8-hydroxy-chlorpromazine in urine.

Authors:  P Turano; C Canton; W J Turner; S Merlis
Journal:  Agressologie       Date:  1968 Mar-Apr

2.  Photodecomposition of some substituted phenothiazines.

Authors:  D Sharples
Journal:  J Pharm Pharmacol       Date:  1981-04       Impact factor: 3.765

3.  Phenothiazine drug metabolites: dopamine D2 receptor, alpha 1- and alpha 2-adrenoceptor binding.

Authors:  P A Hals; H Hall; S G Dahl
Journal:  Eur J Pharmacol       Date:  1986-06-24       Impact factor: 4.432

4.  Effects of levomepromazine, chlorpromazine and their sulfoxides on isolated rat atria.

Authors:  S Dahl; H Refsum
Journal:  Eur J Pharmacol       Date:  1976-06       Impact factor: 4.432

5.  Identification of O-demethylated and ring-hydroxylated metabolites of methotrimeprazine (levomepromazine) in man.

Authors:  H Johnsen; S G Dahl
Journal:  Drug Metab Dispos       Date:  1982 Jan-Feb       Impact factor: 3.922

6.  Interactions of neuroleptic metabolites with dopaminergic, alpha adrenergic and muscarinic cholinergic receptors.

Authors:  D B Bylund
Journal:  J Pharmacol Exp Ther       Date:  1981-04       Impact factor: 4.030

7.  Binding affinity of levomepromazine and two of its major metabolites of central dopamine and alpha-adrenergic receptors in the rat.

Authors:  S G Dahl; H Hall
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

8.  Anti-apomorphine effects of phenothiazine drug metabolites.

Authors:  E Morel; K G Lloyd; S G Dahl
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

9.  The presence of 7-hydroxychlorpromazine in CSF of chloropromazine-treated patients.

Authors:  G Alfredsson; M Lindberg; G Sedvall
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

10.  Muscarinic cholinergic and histamine H1 receptor binding of phenothiazine drug metabolites.

Authors:  P A Hals; H Hall; S G Dahl
Journal:  Life Sci       Date:  1988       Impact factor: 5.037

View more
  2 in total

1.  Theoretical study on the metabolic mechanisms of levmepromazine by cytochrome P450.

Authors:  Yongting Wang; Qiu Chen; Zhiyu Xue; Yan Zhang; Zeqin Chen; Ying Xue
Journal:  J Mol Model       Date:  2016-09-13       Impact factor: 1.810

Review 2.  Levomepromazine for schizophrenia.

Authors:  Parthipan Sivaraman; Ranganath D Rattehalli; Mahesh B Jayaram
Journal:  Cochrane Database Syst Rev       Date:  2010-10-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.